首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1599661篇
  免费   133611篇
  国内免费   2575篇
耳鼻咽喉   21663篇
儿科学   52939篇
妇产科学   46266篇
基础医学   227870篇
口腔科学   47287篇
临床医学   140808篇
内科学   314498篇
皮肤病学   34096篇
神经病学   130153篇
特种医学   64776篇
外国民族医学   475篇
外科学   244012篇
综合类   39706篇
现状与发展   3篇
一般理论   544篇
预防医学   122716篇
眼科学   36427篇
药学   121278篇
  2篇
中国医学   2976篇
肿瘤学   87352篇
  2018年   14773篇
  2016年   12913篇
  2015年   15045篇
  2014年   20686篇
  2013年   31387篇
  2012年   42604篇
  2011年   44804篇
  2010年   26370篇
  2009年   25334篇
  2008年   43055篇
  2007年   45280篇
  2006年   46104篇
  2005年   44727篇
  2004年   44157篇
  2003年   42234篇
  2002年   41348篇
  2001年   75719篇
  2000年   78367篇
  1999年   66425篇
  1998年   17744篇
  1997年   16348篇
  1996年   16325篇
  1995年   16026篇
  1994年   15075篇
  1993年   14221篇
  1992年   55442篇
  1991年   53795篇
  1990年   52574篇
  1989年   50855篇
  1988年   47238篇
  1987年   46576篇
  1986年   44302篇
  1985年   42852篇
  1984年   32040篇
  1983年   27578篇
  1982年   16150篇
  1981年   14442篇
  1980年   13573篇
  1979年   30466篇
  1978年   21074篇
  1977年   17771篇
  1976年   16702篇
  1975年   17587篇
  1974年   21497篇
  1973年   20688篇
  1972年   18869篇
  1971年   17777篇
  1970年   16301篇
  1969年   15281篇
  1968年   13954篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications.  相似文献   
2.
3.
4.
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered.  相似文献   
5.
6.
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass.  相似文献   
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号